<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:32:55Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9283735" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9283735</identifier>
        <datestamp>2022-07-15</datestamp>
        <setSpec>cts</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="cts13286" xml:lang="en" article-type="brief-report">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Clin Transl Sci</journal-id>
              <journal-id journal-id-type="iso-abbrev">Clin Transl Sci</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1752-8062</journal-id>
              <journal-id journal-id-type="publisher-id">CTS</journal-id>
              <journal-title-group>
                <journal-title>Clinical and Translational Science</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1752-8054</issn>
              <issn pub-type="epub">1752-8062</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9283735</article-id>
              <article-id pub-id-type="pmcid">PMC9283735</article-id>
              <article-id pub-id-type="pmc-uid">9283735</article-id>
              <article-id pub-id-type="pmid">35439347</article-id>
              <article-id pub-id-type="pmid">35439347</article-id>
              <article-id pub-id-type="doi">10.1111/cts.13286</article-id>
              <article-id pub-id-type="publisher-id">CTS13286</article-id>
              <article-id pub-id-type="other">CTS-2021-0379</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Brief Report</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Brief Reports</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A phase I randomized, <styled-content style="fixed-case" toggle="no">double‐blind</styled-content>, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects</article-title>
                <alt-title alt-title-type="right-running-head">Subcutaneous rezafungin for human safety and PK</alt-title>
                <alt-title alt-title-type="left-running-head">Gu et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="cts13286-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Gu</surname>
                    <given-names>Kenan</given-names>
                  </name>
                  <xref rid="cts13286-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>kenan.gu@nih.gov</email>
                  </address>
                </contrib>
                <contrib id="cts13286-cr-0002" contrib-type="author">
                  <name>
                    <surname>Ruff</surname>
                    <given-names>Dennis</given-names>
                  </name>
                  <xref rid="cts13286-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cts13286-cr-0003" contrib-type="author">
                  <name>
                    <surname>Key</surname>
                    <given-names>Cassandra</given-names>
                  </name>
                  <xref rid="cts13286-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cts13286-cr-0004" contrib-type="author">
                  <name>
                    <surname>Thompson</surname>
                    <given-names>Marissa</given-names>
                  </name>
                  <xref rid="cts13286-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cts13286-cr-0005" contrib-type="author">
                  <name>
                    <surname>Jiang</surname>
                    <given-names>Shoshanna</given-names>
                  </name>
                  <xref rid="cts13286-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cts13286-cr-0006" contrib-type="author">
                  <name>
                    <surname>Sandison</surname>
                    <given-names>Taylor</given-names>
                  </name>
                  <xref rid="cts13286-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cts13286-cr-0007" contrib-type="author">
                  <name>
                    <surname>Flanagan</surname>
                    <given-names>Shawn</given-names>
                  </name>
                  <xref rid="cts13286-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="cts13286-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <institution>National Institute of Allergy and Infectious Diseases</institution>
                <city>Rockville</city>
                <named-content content-type="country-part">Maryland</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cts13286-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>ICON Early Phase Services Clinical Research Unit</institution>
                <city>San Antonio</city>
                <named-content content-type="country-part">Texas</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cts13286-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <institution>Emmes Company, LLC</institution>
                <city>Rockville</city>
                <named-content content-type="country-part">Maryland</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cts13286-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <institution>Cidara Therapeutics</institution>
                <city>San Diego</city>
                <named-content content-type="country-part">California</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Kenan Gu, Division of Microbiology and Infectious Diseases, NIAID/NIH, 5601 Fishers Lane, Room 7G28 (MSC 9826), Bethesda, MD 20892‐9826, USA.<break/>
Email: <email>kenan.gu@nih.gov</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>04</day>
                <month>5</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>7</month>
                <year>2022</year>
              </pub-date>
              <volume>15</volume>
              <issue seq="40">7</issue>
              <issue-id pub-id-type="doi">10.1111/cts.v15.7</issue-id>
              <fpage>1592</fpage>
              <lpage>1598</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>18</day>
                  <month>3</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>08</day>
                  <month>11</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>04</day>
                  <month>4</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2022 ASCPT.-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">Clinical and Translational Science</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:CTS-15-1592.pdf"/>
              <abstract>
                <title>Abstract</title>
                <p>Rezafungin is a novel echinocandin being developed for the treatment and prevention of invasive fungal infections. The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and pharmacokinetics of rezafungin after subcutaneous (s.c.) administration. The study design consisted of six sequential cohorts of eight subjects, except for the first cohort with four subjects. The subjects were randomized in a 3:1 ratio of rezafungin to placebo and were to receive a single dose of 1, 10, 30, 60, 100, or 200 mg. The most common adverse events (AEs) were increased alanine aminotransferase and sinus bradycardia (unsolicited) and erythema at the injection site (solicited). Unsolicited AEs were generally mild to moderate and not rezafungin‐related. Although the study was terminated after the 10 mg dose cohort due to concerns of potential increased severity of injection site reactions, no predetermined dose escalation halting criteria were met. Following the 10 mg single s.c. dose of rezafungin (<italic toggle="no">n</italic> = 6), the geometric mean (GM) maximum concentration (<italic toggle="no">C</italic>
<sub>max</sub>) was 105.0 ng/ml and the median time to <italic toggle="no">C</italic>
<sub>max</sub> was 144 h. The GM area under the concentration‐time curve was 32,770 ng*h/ml. The median estimated terminal half‐life was 193 h. The GM apparent oral clearance was 0.255 L/h and the GM apparent volume of distribution was 68.5 L. This study demonstrates that a single s.c. dose of rezafungin in healthy adult subjects: (1) did not result in serious AEs, death, or withdrawal from the study due to an AE; and (2) produced a pharmacokinetic profile with long exposure period postadministration. In an effort to reduce the occurrence of injection site reactions, a re‐evaluation of the rezafungin s.c. formulation could be considered in the future.</p>
              </abstract>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>National Institutes of Allergy and Infectious Diseases</funding-source>
                  <award-id>HHSN272201500007I</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="2"/>
                <page-count count="7"/>
                <word-count count="3521"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>July 2022</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:15.07.2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="CTS13286-cit-2001"><string-name><surname>Gu</surname><given-names>K</given-names></string-name>, <string-name><surname>Ruff</surname><given-names>D</given-names></string-name>, <string-name><surname>Key</surname><given-names>C</given-names></string-name>, et al. <article-title>A phase I randomized, <styled-content style="fixed-case" toggle="no">double‐blind</styled-content>, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects</article-title>. <source>Clin Transl Sci</source>. <year>2022</year>;<volume>15</volume>:<fpage>1592</fpage>‐<lpage>1598</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cts.13286</pub-id>
</mixed-citation>
              </p>
              <fn-group id="cts13286-ntgp-0001">
                <fn id="cts13286-note-0001">
                  <p><bold>Funding information</bold>This project has been funded by the National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), with funds from a phase I Clinical Trial Units for Therapeutics program award to ICON Plc (Contract No. HHSN272201500007I) for the conduct of the study at ICON Early Phase Services Clinical Research Unit.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="cts13286-body-0001">
            <p>
              <boxed-text position="anchor" content-type="box">
                <caption>
                  <title>Study Highlights</title>
                </caption>
                <p>
                  <list list-type="simple" id="cts13286-list-0001">
                    <list-item id="cts13286-li-0001">
                      <p>
                        <bold>WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?</bold>
                      </p>
                    </list-item>
                  </list>
                </p>
                <p>Currently marketed antifungal agents of the echinocandin class are dosed by i.v. once daily and are therefore not practical for prolonged or outpatient prophylaxis. Rezafungin is an investigational echinocandin (currently in phase III trials studying once‐weekly i.v. administration) that has excellent activity against clinically relevant <italic toggle="yes">Candida</italic> and <italic toggle="yes">Aspergillus</italic> spp. and <italic toggle="yes">Pneumocystis jirovecii</italic>, a prolonged half‐life allowing for longer dosing intervals, and a stability/solubility profile that allows for the possibility of subcutaneous (s.c.) dosing.
<list list-type="simple" id="cts13286-list-0002"><list-item id="cts13286-li-0002"><p><bold>WHAT QUESTION DID THE STUDY ADDRESS?</bold></p></list-item></list>
</p>
                <p>The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and pharmacokinetics (PKs) of rezafungin after s.c. administration.
<list list-type="simple" id="cts13286-list-0003"><list-item id="cts13286-li-0003"><p><bold>WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?</bold></p></list-item></list>
</p>
                <p>This study provided safety data regarding s.c. administration of rezafungin. Despite common solicited injection site reactions, s.c. administration of 10 mg of rezafungin did not result in serious adverse event (AEs), death, or withdrawals due to an AE in healthy adult subjects. The study also showed that rezafungin had a PK profile with a long exposure period.
<list list-type="simple" id="cts13286-list-0004"><list-item id="cts13286-li-0004"><p><bold>HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?</bold></p></list-item></list>
</p>
                <p>In an effort to reduce the occurrence of injection site reactions, these findings may lead to a future re‐evaluation of the s.c. formulation of rezafungin.</p>
              </boxed-text>
            </p>
            <sec id="cts13286-sec-0003">
              <title>INTRODUCTION</title>
              <p>Rezafungin is an investigational antifungal agent with the favorable efficacy and safety profiles of its echinocandin class. Currently marketed echinocandins are dosed by i.v. infusions once daily<xref rid="cts13286-bib-0001" ref-type="bibr"><sup>1</sup></xref> and are therefore not practical for prolonged or outpatient prophylaxis. The prolonged half‐life of rezafungin allows for i.v. dosing 400 mg loading dose, followed by 200 mg once weekly in phase II and phase III studies,<xref rid="cts13286-bib-0002" ref-type="bibr"><sup>2</sup></xref> and its stability/solubility enables s.c. formulation<xref rid="cts13286-bib-0003" ref-type="bibr"><sup>3</sup></xref> with moderate to high bioavailability in rats and monkeys (up to ~ 80%). The smaller rezafungin dose requirement also supports the possibility of s.c. dosing volume.</p>
              <p>To our knowledge, this is the first study to evaluate the safety, tolerability, and pharmacokinetics (PKs) of single ascending doses of rezafungin administered s.c. in healthy adults.</p>
            </sec>
            <sec id="cts13286-sec-0004">
              <title>METHODS AND MATERIALS</title>
              <sec id="cts13286-sec-0005">
                <title>Study design and treatments</title>
                <p>This was a phase I, single‐center, prospective, randomized, double‐blind trial of single‐ascending doses of rezafungin administered by s.c. injection to six cohorts of healthy adult subjects to evaluate its safety, tolerability, and PKs.</p>
                <p>Rezafungin injection for s.c. use (100 mg/ml), containing rezafungin acetate, and mannitol, was manufactured by Patheon Ferentinoc. The placebo was 5% dextrose injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection.</p>
                <p>Participants were admitted to the clinical research unit (CRU) for check‐in for clinical evaluations the day before dosing. They were randomized and dosed on day 1 of the study and confined to the CRU for 7 days for continued assessments and sample collections. Follow‐up visits or telephone calls were conducted on day 14 (± 1 day), day 21 (± 1 day), and day 30 (± 1 day).</p>
              </sec>
              <sec id="cts13286-sec-0006">
                <title>Ethics</title>
                <p>The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines as required by 21 Code of Federal Regulations. All study‐related documents were approved by IntegReview Institutional Review Board. All subjects signed an informed consent form prior to participating in the study.</p>
              </sec>
              <sec id="cts13286-sec-0007">
                <title>Subjects</title>
                <p>A total of 44 subjects were planned to be enrolled into one of six cohorts: cohort 1 (1 mg) with four subjects and cohorts 2 to 6 (10, 30, 60, 100, and 200 mg) with eight subjects each. Subjects in each cohort were randomized in a 3:1 ratio (rezafungin to placebo). Eligible participants were healthy men and women 18 to 45 years old with body mass index (BMI) of 18.5 to 35.0 kg/m<sup>2</sup>, a minimum weight of 50 kg, and adequate venous access for blood collection. Exclusion criteria included history of hypersensitivity or allergic reactions to echinocandins, receipt of any live or killed vaccines or immunoglobulins within 14 days of dosing, or previous participation in any rezafungin trial. Subjects were excluded if they were positive for hepatitis B, hepatitis C, or HIV serology; had clinical laboratory values outside the reference ranges prior to dosing; had abnormal electrocardiogram (ECG) findings; or presented with any clinically significant condition in the opinion of the investigator.</p>
              </sec>
              <sec id="cts13286-sec-0008">
                <title>Dose escalation criteria</title>
                <p>Two sentinel subjects were to be admitted initially in each cohort (except for cohort 1) and randomized 1:1 to receive rezafungin or placebo. All sentinel subject safety data through day 30 was reviewed by the principal investigator prior to dosing the remainder of the cohort. Safety data for each cohort through day 30 was to be confirmed by review of objective predefined criteria before continuing to the next cohort.</p>
              </sec>
              <sec id="cts13286-sec-0009">
                <title>Safety and tolerability assessments</title>
                <p>Safety was assessed by occurrence of solicited and unsolicited adverse events (AEs), serious AEs (SAEs), and clinical evaluation (including clinical laboratory tests, ECGs, physical examinations, and vital signs) on select days from dosing through day 30. Tolerability was assessed by occurrence of solicited local reactogenicity symptoms (injection site evaluation) from dosing to day 30.</p>
                <p>Solicited AEs, as specified in the case report form and recorded through the regular collection of data, comprised reactogenicity symptoms localized to the area of the s.c. dose, including pain, tenderness, pruritus, ecchymosis, induration/swelling, erythema, nodule, and ulceration. Unsolicited AEs were those not specified in the case report form and recorded as volunteered by subjects or other unsolicited manner. AEs were recorded from dosing to the final follow‐up visit and graded based on severity as mild (grade 1), moderate (grade 2), or severe (grade 3) and assessed to be related or not related to the study product by the study physician. AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA) version 23.1.</p>
                <p>Safety and clinical laboratory tests were conducted on blood and urine samples collected after subjects had fasted for at least 8 h and included hematology, coagulation, blood chemistry, and dipstick urinalysis.</p>
              </sec>
              <sec id="cts13286-sec-0010">
                <title>Halting criteria</title>
                <p>Cohort escalation would be halted if: (1) two or more subjects in a cohort experienced the same grade 2 (or higher) drug‐related AE in the same MedDRA‐coded high‐level group term through day 30; (2) two or more subjects within a cohort experienced postdose QTcF greater than 500 or change from baseline greater than 60 ms; or (3) any subject experienced skin ulceration of any grade at an injection site.</p>
              </sec>
              <sec id="cts13286-sec-0011">
                <title>Pharmacokinetic assessments</title>
                <p>PK profiles of rezafungin were to be assessed by measurement of drug levels in plasma after s.c. administration in each cohort (except for cohort 1).</p>
                <p>Plasma for PK analysis was collected at 0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, 144, 312 (day 14), and 696 (day 30) h postdose. Rezafungin concentrations were determined by a validated liquid chromatography‐tandem accurate mass spectrometry method with a lower limit of quantitation of 10 ng/ml. PK sampling was not conducted for cohort 1 participants for 1 mg dose, because it was anticipated that rezafungin concentrations would be undetectable in plasma at this dose level based on human i.v. dose concentration data,<xref rid="cts13286-bib-0004" ref-type="bibr"><sup>4</sup></xref> and this dose was to evaluate local tolerability. Bioanalytical data collection and analysis were completed with Analyst version 1.6.3/ICON LIMS (iBIO) version 1.7.11.</p>
              </sec>
              <sec id="cts13286-sec-0012">
                <title>Statistical analyses</title>
                <p>No formal sample‐size calculations or formal hypothesis tests were conducted. When presented for a proportion, 95% confidence intervals were calculated using the Wilson Score method. Rezafungin PK parameters were estimated by noncompartmental analysis (NCA) using Phoenix WinNonlin version 8.2 or later (Certara, Princeton, NJ). The Lambda Z acceptance criteria used in the NCAs were as follows: rsq_adjusted greater than or equal to 0.90, span greater than or equal to 2.0 half‐lives, and that the analysis include at least two timepoints after time to maximum plasma concentration (<italic toggle="yes">T</italic>
<sub>max</sub>). Terminal phase parameters will be excluded if they do not meet the Lambda Z acceptance criteria.</p>
                <p>SAS version 9.4 or above or R version 3.2 or above were used to generate tables, figures, and listings.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="cts13286-sec-0013">
              <title>RESULTS</title>
              <p>The study was terminated after cohort 2 completion due to the number of subjects who experienced solicited AEs following s.c. administration. These events raised concerns of increased severity of injection site reactions with higher doses.</p>
              <sec id="cts13286-sec-0014">
                <title>Disposition and demographics</title>
                <p>Four subjects were enrolled and received study product in cohort 1 (three rezafungin and one placebo), and eight subjects were enrolled and received the study product in cohort 2 (six rezafungin and two placebo). Two randomized subjects in cohort 2 (one in the 10 mg dose group and 1 in the placebo group) terminated early from the study prior to receiving any study product and were excluded from safety and PK analyses.</p>
                <p>Across all 14 randomized subjects, there were 13 men (93%) and one woman (7%). Half of the subjects were Hispanic or Latino (50%). The majority of the subjects were White (57%). The mean age for all subjects was 33.6 years (range: 23–45 years). At baseline, average height was 175.49 cm (range: 166.4–189.5 cm), average weight was 84.54 kg (range: 66.7–117.1 kg), and average BMI was 27.25 kg/m<sup>2</sup> (range: 22.7–32.6 kg/m<sup>2</sup>).</p>
              </sec>
              <sec id="cts13286-sec-0015">
                <title>Safety and tolerability results</title>
                <p>All 12 subjects that received the study product were included in the safety analysis population. There were no SAEs, deaths, or withdrawals from the study due to an AE, and no halting criteria were met.</p>
                <p>Unsolicited AEs were generally mild and not rezafungin‐related. The most common unsolicited AEs were increased sinus bradycardia (2 subjects [67%] of 3 who received rezafungin in cohort 1) and increased alanine aminotransferase (2 subjects [33%] of 6 who received rezafungin in cohort 2). A single subject in cohort 1 developed severe bradycardia, which was asymptomatic and determined to not be rezafungin‐related. Five separate AEs, which occurred in three subjects in cohort 2, were considered mild but deemed related to rezafungin. One subject experienced three of these AEs: elevated white blood cell, monocyte, and basophil counts. The possible relationship to rezafungin was based on a temporal association to dosing. One subject had skin pigmentation at the injection site. This was considered related to rezafungin. One subject had a mild headache deemed related to rezafungin given the temporal association to dosing. In all cases, the events were resolved.</p>
                <p>Solicited reactogenicity symptoms is presented in Table <xref rid="cts13286-tbl-0001" ref-type="table">1</xref>. These findings were mild to moderate in intensity and considered to be related to rezafungin. None of the changes were deemed serious and there were no erosions or skin ulcers associated with these injection site changes. Resolution or reduction in nodule size generally occurred over 2–4 weeks, and no treatment of the injection area was necessary.</p>
                <table-wrap position="float" id="cts13286-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Number and percentage of subjects experiencing solicited reactogenicity symptoms by symptom and dose group</p>
                  </caption>
                  <table frame="hsides" rules="all">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Symptom</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Any dose (<italic toggle="yes">N</italic> = 9)</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">1 mg (<italic toggle="yes">N</italic> = 3)</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">10 mg (<italic toggle="yes">N</italic> = 6)</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Placebo (<italic toggle="yes">N</italic> = 3)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <italic toggle="yes">n</italic>
                        </th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">%</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <italic toggle="yes">n</italic>
                        </th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">%</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <italic toggle="yes">n</italic>
                        </th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">%</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <italic toggle="yes">n</italic>
                        </th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">%</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Any symptom</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">78</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">45, 94</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">33</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6, 79</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">100</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">61, 100</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Pain</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">33</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12, 65</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">33</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6, 79</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">33</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10, 70</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Tenderness</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">44</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19, 73</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">67</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">30, 90</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Pruritus (itching)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2, 43</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">17</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3, 56</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Ecchymosis (bruising), functional grade</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6, 55</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">33</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10, 70</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Ecchymosis (bruising), measurement grade</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2, 43</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">17</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3, 56</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Induration (hardness)/swelling, functional grade</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2, 43</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">17</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3, 56</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Induration (hardness)/swelling, measurement grade</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2, 43</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">17</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3, 56</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Erythema (redness), functional grade</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">67</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">35, 88</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">100</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">61, 100</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Erythema (redness), measurement grade</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">67</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">35, 88</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">100</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">61, 100</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Nodule, functional grade</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">56</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27, 81</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">83</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">44, 97</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Nodule, measurement grade</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">44</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19, 73</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">67</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">30, 90</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Ulceration, functional grade</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Ulceration, measurement grade</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cts13286-ntgp-0002">
                    <fn id="cts13286-note-0002">
                      <p><italic toggle="yes">Note</italic>: <italic toggle="yes">N</italic> = Number of subjects in safety population.</p>
                    </fn>
                    <fn id="cts13286-note-0003">
                      <p>Abbreviation: CI, confidence interval.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="cts13286-sec-0016">
                <title>Pharmacokinetic results</title>
                <p>PK data were available from all six subjects in cohort 2 who received rezafungin (10 mg) s.c. dose and presented in Table <xref rid="cts13286-tbl-0002" ref-type="table">2</xref>.</p>
                <table-wrap position="float" id="cts13286-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Summary statistics of rezafungin PK parameters in plasma—10 mg dose group</p>
                  </caption>
                  <table frame="hsides" rules="all">
                    <col align="left" span="1"/>
                    <col align="char" char="." span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="char" char="." span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Parameter (units)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <italic toggle="yes">N</italic>
                        </th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Mean</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Standard deviation</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Minimum</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Median</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Maximum</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Geometric mean</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Geometric CV%</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">C</italic><sub>max</sub> (ng/ml)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">108.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">29.50</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">72.6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">105.4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">154</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">105.0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">28</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">T</italic><sub>max</sub> (h)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">120.0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">40.16</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">48.0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">144.0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">144</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">112.1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">47</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">AUC<sub>0‐last</sub> (ng*h/ml)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">33,950</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9989</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22,400</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">31,950</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">49,400</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">32,770</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">30</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">AUC<sub>0‐inf</sub> (ng*h/ml)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">40,140</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9626</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">29,100</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">37,100</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">53,200</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">39,230</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">24</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">t</italic><sub>1/2</sub> (h)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">188.2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">29.30</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">140</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">193.0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">219</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">186.2</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">17</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">CL/F (L/h)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0.2608</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.06142</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.188</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.2700</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.344</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.2550</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">24</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">V</italic><sub>z</sub>/F (L)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">71.88</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22.52</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">38.0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">78.40</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">95.6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">68.50</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">38</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cts13286-ntgp-0003">
                    <fn id="cts13286-note-0004">
                      <p><italic toggle="yes">Notes</italic>: Lambda Z acceptance criteria were as follows: <italic toggle="yes">r</italic><sub>sq_adjusted</sub> ≥ 0.90, span ≥2.0 half‐lives, and at least two timepoints after <italic toggle="yes">T</italic>
<sub>max</sub>.</p>
                    </fn>
                    <fn id="cts13286-note-0005">
                      <p>Points used in the NCA were manually selected and include <italic toggle="yes">T</italic>
<sub>max</sub> for some participants.</p>
                    </fn>
                    <fn id="cts13286-note-0006">
                      <p>Abbreviations: AUC<sub>0‐inf</sub>, area under the concentration‐time curve to infinity; AUC<sub>0‐last</sub>, area under the concentration‐time curve from the time of dosing to the last measurable concentration; CL/F, apparent clearance; <italic toggle="yes">C</italic>
<sub>max</sub>, maximum plasma concentration; CV%, percent coefficient of variation; PK, pharmacokinetic; <italic toggle="yes">t</italic>
<sub>1/2</sub>, terminal half‐life; <italic toggle="yes">T</italic>
<sub>max</sub>, time to maximum plasma concentration; <italic toggle="yes">V</italic>
<sub>z</sub>/F, apparent volume of distribution.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>The median <italic toggle="yes">T</italic>
<sub>max</sub> was 144 h (range: 48 to 144 h). The geometric mean (GM) maximum plasma concentration was 105.0 ng/ml (coefficient of variation [CV] 28%). Rezafungin concentrations were still detected in five of six subjects through the last PK sample timepoint on day 30 (696 h postdose). The GM of the area under the concentration‐time curve from the time of dosing to the last measurable concentration (nominal time 696 h postdose; AUC<sub>[0‐last]</sub>) was 32,770 ng*h/ml (CV 30%). The estimated GM AUC to infinity (AUC<sub>(0‐inf)</sub>) was 39,230 ng*h/ml (CV 24%). The estimated median terminal half‐life (<italic toggle="yes">t</italic>
<sub>1/2</sub>) was 193.0 h (range: 140 to 219 h). The GM apparent oral clearance (CL/F) was 0.255 L/h (CV 24%). The GM volume of distribution (<italic toggle="yes">V</italic>
<sub>z</sub>/F) was estimated to be 68.5 L (CV 38%).</p>
                <p>Figure <xref rid="cts13286-fig-0001" ref-type="fig">1</xref> presents the geometric mean plasma concentration‐time profile of rezafungin following s.c. administration.</p>
                <fig position="float" fig-type="FIGURE" id="cts13286-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Pharmacokinetic results: semi‐log geometric mean plasma concentration‐time profile. The semi‐log mean plasma concentration‐time profile was demonstrated by the geometric mean and percent coefficient of variation of plasma concentrations over time of six subjects that received 10 mg of rezafungin (cohort 2) subcutaneously. Plasma for pharmacokinetic analysis was collected from subjects at predose and several timepoints through 696 h (29 days). The rezafungin concentrations were determined by a validated liquid‐chromatography tandem mass spectrometry (lower limit of quantitation of 10 ng/ml). The i.v. concentration‐time curve of dose adjusted i.v. results (400 mg i.v. divided by 40 mg) are presented for comparison with the s.c. results obtained from this study. —, SC GM; ·····, SC CV%; – –, IV GM*. *Copyright © 2022 Ong et al.<xref rid="cts13286-bib-0006" ref-type="bibr"><sup>6</sup></xref> This is an open‐access article distributed under the terms of the Creative Commons Attribution 4.0 International license</p>
                  </caption>
                  <graphic xlink:href="CTS-15-1592-g001" position="anchor" id="jats-graphic-1"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion" id="cts13286-sec-0017">
              <title>DISCUSSION</title>
              <p>The study was terminated after cohort 2 (10 mg) due to concerns of tolerability at higher doses. However, no dose escalation halting criteria were met, no subjects withdrew due to AEs, and no systemic AEs occurred that were deemed intolerable for subjects given 1 mg or 10 mg rezafungin subcutaneously. No biopsies of the injection site were taken from subjects who presented with solicited local injection site findings, but given the character and location of the nodules and the absence of skin erosion or ulcers, it is speculated that rezafungin, as formulated for s.c. administration in this study, resulted in a local panniculitis. The injection site reactions in nonclinical species were equivocal and tolerability needed to be assessed clinically. Assessment of unsolicited AEs from this study suggests that rezafungin was safe in terms of the lack of SAEs and withdrawals due to AEs. There were no ECG, laboratory, or subjective unsolicited complaints.</p>
              <p>PK results from this study demonstrated a slow rezafungin absorption rate, with peak rezafungin plasma concentration observed around 7 days postdose. Absorption appeared extensive following s.c. dose administration. The PK profile of rezafungin demonstrated a long exposure period (nearly 1 month). After loosening the terminal phase elimination constant (λ<sub>z</sub>) acceptance criteria from the analysis plan prespecified requirements for a span greater than or equal to three half‐lives and at least three timepoints after <italic toggle="yes">T</italic>
<sub>max</sub> to span greater than or equal to two half‐lives and at least two timepoints after <italic toggle="yes">T</italic>
<sub>max</sub> in addition to hand selecting the sample timepoints included in the calculation to include the <italic toggle="yes">T</italic>
<sub>max</sub> sample, terminal phase PK parameters (AUC<sub>(0‐inf)</sub>, <italic toggle="yes">t</italic>
<sub>1/2</sub>, CL/F, and apparent <italic toggle="yes">V</italic>
<sub>z</sub>/F) were able to be estimated.</p>
              <p>Echinocandins, which have been in clinical use globally for over 20 years, are only available via i.v. injection.<xref rid="cts13286-bib-0005" ref-type="bibr"><sup>5</sup></xref> No clinical studies have been conducted previously with s.c. rezafungin. Phase I and II clinical trials of i.v. rezafungin have been completed and provide insight into the potential for efficacy and systemic safety of s.c. rezafungin.<xref rid="cts13286-bib-0006" ref-type="bibr"><sup>6</sup></xref> In a human clinical study,<xref rid="cts13286-bib-0004" ref-type="bibr"><sup>4</sup></xref> the plasma PKs of rezafungin was well‐characterized following single i.v. doses of 50, 100, 200, and 400 mg. <italic toggle="yes">T</italic>
<sub>max</sub> was observed at the end of infusion at ~ 1 h after the start of rezafungin infusion for all doses. Total body clearance was slow (~ 0.2 L/h) throughout the dose levels with a long apparent <italic toggle="yes">t</italic>
<sub>1/2</sub> (<italic toggle="yes">t</italic>
<sub>1/2</sub> ranged from 127–146 h). The rezafungin <italic toggle="yes">T</italic>
<sub>max</sub> following s.c. injection occurred ~ 6 days later. Rezafungin elimination following s.c. injection appeared quite long, similar to that of the i.v. injection with a long half‐life<xref rid="cts13286-bib-0007" ref-type="bibr"><sup>7</sup></xref> as shown in Figure <xref rid="cts13286-fig-0001" ref-type="fig">1</xref>. After approximately a month of 10 mg rezafungin s.c. administration, the rezafungin concentrations were still detected above 10 ng/ml in human systemic circulation. By comparing AUC<sub>(0‐last)</sub> results between s.c. and i.v. administration routes, the absolute bioavailability of the s.c. formulation relative to previously reported clinical i.v. results could be estimated at ~ 65%.<xref rid="cts13286-bib-0007" ref-type="bibr"><sup>7</sup></xref>
</p>
            </sec>
            <sec sec-type="COI-statement" id="cts13286-sec-0019">
              <title>CONFLICT OF INTEREST</title>
              <p>Shawn Flanagan and Taylor Sandison are employees and stockholders of Cidara Therapeutics, Inc. All other authors declared no competing interests for this work.</p>
            </sec>
            <sec id="cts13286-sec-0020">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p>K.G., S.F., T.S., M.T., and S.J. wrote the manuscript. K.G., D.R., S.F., and T.S. designed the research. D.R. and C.K. performed the research. M.T., S.J., and K.G. analyzed the data.</p>
            </sec>
          </body>
          <back>
            <ack id="cts13286-sec-0018">
              <title>ACKNOWLEDGMENTS</title>
              <p>From the National Institute of Allergy and Infectious Diseases (NIAID), Maureen Mehigan was the clinical project manager, Tatiana Beresnev was the medical monitor, and Carmelle Norris‐Tra was the medical officer. From Emmes Company, Aya Nakamura was the project manager and Crystal Chen was lead statistician. The medical writing department at ICON GPHS wrote the manuscript in collaboration with all authors.</p>
            </ack>
            <ref-list content-type="cited-references" id="cts13286-bibl-0001">
              <title>REFERENCES</title>
              <ref id="cts13286-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="cts13286-cit-0001"><string-name><surname>Epstein</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Seo</surname><given-names>SK</given-names></string-name>, <string-name><surname>Brown</surname><given-names>JM</given-names></string-name>, <string-name><surname>Papanicolaou</surname><given-names>GA</given-names></string-name>. <article-title>Echinocandin prophylaxis in patients undergoing cell transplantation and other treatments for haematological malignancies</article-title>. <source>J Antimicrob Chemother</source>. <year>2018</year>;<volume>73</volume>(<issue>S1</issue>):<fpage>i60</fpage>‐<lpage>i72</lpage>.<pub-id pub-id-type="pmid">29304213</pub-id></mixed-citation>
              </ref>
              <ref id="cts13286-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="cts13286-cit-0002"><string-name><surname>Thompson</surname><given-names>GR</given-names></string-name>, <string-name><surname>Soriano</surname><given-names>A</given-names></string-name>, <string-name><surname>Skoutelis</surname><given-names>A</given-names></string-name>, et al. <article-title>Rezafungin versus Caspofungin in a phase 2, randomized, double‐blind study for the treatment of Candidemia and invasive candidiasis: the STRIVE trial</article-title>. <source>Clin Infect Dis</source>. <year>2021</year>;<volume>73</volume>(<issue>11</issue>):<fpage>e3647</fpage>‐<lpage>e3655</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciaa1380</pub-id> Erratum in: <italic toggle="yes">Clin Infect Dis</italic>. 2021;73(3):561‐562.<pub-id pub-id-type="pmid">32955088</pub-id></mixed-citation>
              </ref>
              <ref id="cts13286-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="cts13286-cit-0003"><string-name><surname>Ong</surname><given-names>V</given-names></string-name>, <string-name><surname>Hough</surname><given-names>G</given-names></string-name>, <string-name><surname>Schlosser</surname><given-names>M</given-names></string-name>, <string-name><surname>Bartizal</surname><given-names>K</given-names></string-name>, <string-name><surname>Balkovec</surname><given-names>JM</given-names></string-name>, et al. <article-title>Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2016</year>;<volume>60</volume>(<issue>11</issue>):<fpage>6872</fpage>‐<lpage>6879</lpage>.<pub-id pub-id-type="pmid">27620474</pub-id></mixed-citation>
              </ref>
              <ref id="cts13286-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="cts13286-cit-0004"><string-name><surname>Sandison</surname><given-names>T</given-names></string-name>, <string-name><surname>Ong</surname><given-names>V</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J</given-names></string-name>, <string-name><surname>Thye</surname><given-names>D</given-names></string-name>. <article-title>Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2017</year>;<volume>61</volume>(<issue>2</issue>):<fpage>e01627‐16</fpage>.<pub-id pub-id-type="pmid">27919901</pub-id></mixed-citation>
              </ref>
              <ref id="cts13286-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="cts13286-cit-0005"><string-name><surname>Mroczynska</surname><given-names>M</given-names></string-name>, <string-name><surname>Brillowska‐Dabrowska</surname><given-names>A</given-names></string-name>. <article-title>Review on current status of echinocandins use</article-title>. <source>Antibiotics</source>. <year>2020</year>;<volume>9</volume>(<issue>5</issue>):<fpage>227</fpage>.</mixed-citation>
              </ref>
              <ref id="cts13286-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="cts13286-cit-0006"><string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Perlin</surname><given-names>DS</given-names></string-name>. <article-title>Review of the novel echinocandin antifungal rezafungin: animal studies and clinical data</article-title>. <source>J Fungi</source>. <year>2020</year>;<volume>6</volume>(<issue>4</issue>):<fpage>192</fpage>.</mixed-citation>
              </ref>
              <ref id="cts13286-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="cts13286-cit-0007"><string-name><surname>Ong</surname><given-names>V</given-names></string-name>, <string-name><surname>Willis</surname><given-names>S</given-names></string-name>, <string-name><surname>Watson</surname><given-names>D</given-names></string-name>, <string-name><surname>Sandison</surname><given-names>T</given-names></string-name>, <string-name><surname>Flanagan</surname><given-names>S</given-names></string-name>. <article-title>Metabolism, excretion, and mass balance of [<sup>14</sup>C]‐Rezafungin in animals and humans</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2021</year>;<volume>66</volume>:<fpage>e0139021</fpage>.<pub-id pub-id-type="pmid">34662192</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
